Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Chronic myeloid leukemia (CML) has become a chronic disease, for which the chronic phase is manageable with tyrosine kinase inhibitor (TKI) therapy. Patients with optimal responses to TKIs have achieved long‐term survival, and treatment‐free remission (TFR) has since become an additional treatment goal in CML. In this review, we discuss important factors to consider prior to stopping treatment. In addition, published and presented data with the first‐generation TKI imatinib, as well as current clinical trials evaluating TFR with the second‐generation TKIs dasatinib and nilotinib, are examined. Results obtained outside of clinical trials have been included as well. Because successful TKI discontinuation depends upon accurate BCR‐ABL1 monitoring, emerging technologies are also discussed. Clinical data obtained to date indicate that for many patients who achieve deep molecular response (DMR) on TKI therapy, TFR is a safe treatment goal, and, if the response is lost, patients can expect to regain their responses immediately upon reinitiation of TKI. It is also clear that there remains much room for improvement to make TFR a successful reality for most patients. Data from ongoing trials should help refine decisions as to which patients are the best candidates to attempt TKI discontinuation with safe monitoring in place.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · cited 1×
“Chronic myeloid leukemia (CML) has become a chronic disease—initially, for some patients, with the use of interferon alpha,(1) but primarily with the routine use of tyrosine kinase inhibitor (TKI) therapy (including imatinib, and the second-generation TKIs, dasatinib, nilotinib, and bosutinib).(2) The prevalence of CM…”
BackgroundSelf-citationCortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Self-citationBower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T. M.-L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2866 · Cited by 904
Rousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F. E., Varet, B., Gardembas, M., Etienne, G., Réa, D., Roy, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5797 · Cited by 416 · cited 11×
“The EURO-SKI study (which included patients with any TKI, although a majority were treated with imatinib) used such criteria and reported a 49% probability of loss of MMR.69 However, because of the short follow-up (median of 27 months) and what appears to be a slow but continued drop in the rate of successful TFR over…”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Réa, D., Mauro, M. J., Boquimpani, C., Minami, Y., Lomaia, E., Voloshin, S., Turkina, A., Kim, D.-W., Apperley, J. F., Abdo, A., et al. (2021) · Blood · doi:10.1182/blood.2020009984 · Cited by 342
Self-citationAlves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Radich, J. P., Hochhaus, A., Masszi, T., Hellmann, A., Stentoft, J., Casares, M. T. G., García-Gutiérrez, J. V., Conneally, E., le Coutre, P. D., Gattermann, N., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01205-5 · Cited by 91
Marcé, S., Méndez, A., Xicoy, B., Estrada, N., Cabezón, M., Sturla, A. L., García, M. R., Angona, A., Amat, P., Escribano Serrat, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030779 · Cited by 5
Metadata
- Authors
- Cortes, J., Rea, D., & Lipton, J. H.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2018-11-25
- Volume
- 94
- Issue
- 3
- Pages
- 346-357
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2900357627
- Cited by
- 136
- References
- 4
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors. https://app.cochat.ai/papers/10.1002/ajh.25342
- The paper
- Cortes, J., Rea, D., & Lipton, J. H. (2019). Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors. American Journal of Hematology. https://doi.org/10.1002/ajh.25342
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.